Navigation Links
Neuronascent, Inc. Receives Multiple Fundings for Its Neurogenesis Therapeutic Programs

CLARKSVILLE, Md., Oct. 13 /PRNewswire/ -- Neuronascent, Inc. ( announced today that the Company has received funding from multiple sources to further the development of its novel, neurogenic compounds targeting Alzheimer's disease, depression and ischemia. Neuronascent has received grants and funding from Maryland Department of Business and Economic Development Challenge Investment Program; Maryland Industrial Partnerships in collaboration with University of Maryland, Baltimore; and Jefferson Corner Group I, LLC, a member-managed angel fund located in Charlottesville, Virginia designed to capitalize on the growth in entrepreneurial activity in Charlottesville and other areas. This is the Company's second award from the Challenge Investment Program.

The company's lead compounds, currently in preclinical testing, aim to replace damaged neurons, restore neurons critical to cognition and memory and enhance neuroprotection against neurodegenerative diseases. Results from recent animal studies show a reversal of cognitive loss in aged mice to young levels.

"Our lead compound for Alzheimer's disease may represent the first disease-modifying therapeutic under development," said Judith Kelleher-Andersson, Ph.D., President and Chief Scientific Officer. Dr. Kelleher-Andersson went on to say, "This funding affords us the opportunity to pursue multiple preclinical studies to further develop our lead agents for clinical trials."

Founded in 2004 by Dr. Kelleher-Andersson, Neuronascent, Inc. is a small-molecule central nervous system drug discovery company developing novel therapeutics based on the science of neurogenesis that target Alzheimer's disease, depression and ischemia. Neuronascent has laboratories in Rockville and Walkersville, Maryland.

Safe Harbor Statement

This release contains forward-looking statements, which are made pursuant to the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are commonly identified by words such as "would," "may," "will," "expects," and other terms with similar meaning. Forward-looking statements are based on current beliefs, assumptions and expectations and speak only as of the date of this release and involve risks and uncertainties that could cause actual results to differ materially from current expectations.

SOURCE Neuronascent, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. TriReme Medical Inc. Receives CE Marking for Antares(TM) Coronary Stent System
2. Anthera Completes Special Protocol Assessment With FDA and Receives EMEA Scientific Advice on Development Path Toward Varespladib Approval
3. AstraZeneca Receives Six Months Pediatric Exclusivity for CASODEX(R) (bicalutamide) from the FDA
4. Helix Receives Approval to Open Sites in Germany for its Ongoing Clinical Trial With Topical Interferon Alpha-2b in Patients With Ano-Genital Warts
5. Enobia Pharma Receives FDA Orphan Drug Designation for Hypophosphatasia Product Candidate ENB-0040
6. Cephalon Receives Complete Response Letter Regarding Request for Expanded FENTORA Label for Non-Cancer Breakthrough Pain
7. Theranostics Health Receives Green Light to Perform Clinical Testing
8. StemCor Systems Receives CE Mark for MarrowMiner(TM) System for Bone Marrow Collection
9. Medarex Receives Milestone Payment from Pfizer for Investigational New Drug Application Filing
10. Celator Pharmaceuticals Receives Orphan Drug Designation for Anticancer Agent CPX-351
11. Unique Hearing Aid Receives Patent Protection
Post Your Comments:
(Date:11/25/2015)... -- Henry Schein, Inc., the world,s largest provider of health ... animal health practitioners, will unveil at the Greater New ... Pavilion , which brings together for the first time ... help any practice or laboratory enter the digital age. ... of experts appearing at the Pavilion. --> ...
(Date:11/25/2015)... 25, 2015  Trovagene, Inc. (NASDAQ: TROV ), ... Chief Executive Officer Antonius Schuh, Ph.D., is scheduled to ... Annual Piper Jaffray Healthcare Conference. th ... Palace Hotel in New York ... Mr. Schuh will be available for one-on-one meetings during ...
(Date:11/25/2015)... 25, 2015 Endo International plc (NASDAQ: ENDP ... , President and CEO, will discuss corporate updates at the ... New York on Wednesday, December 2, 2015 ... on Investor Relations, and then the link to the event. ... start time to visit the site and download any streaming ...
Breaking Medicine Technology:
(Date:11/26/2015)... ... November 26, 2015 , ... Jobs in hospital medical laboratories and in the ... healthcare staffing agency Aureus Medical Group . These fields, as well ... those searching for healthcare jobs through the company’s website, , The ...
(Date:11/26/2015)... ... November 26, 2015 , ... Indosoft Inc., developer and ... an application server to improve system efficiency and reliability. , The new Q-Suite 6 ... these standards, the system avoids locking itself into a specific piece of software for ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... recognized once again for its stellar workplace culture with the company’s Cincinnati office ... , Medical Solutions’ Cincinnati office was named a finalist in Cincinnati Business Courier’s ...
(Date:11/25/2015)... ... 25, 2015 , ... For the first time, Vitalalert is donating half of ... campaign. The partnership between the two groups began in 2014 with Vitalalert pledging a ... MAP International was founded in 1954 and is an international Christian-based health organization whose ...
(Date:11/25/2015)... ... November 25, 2015 , ... Wimbledon Health Partners, ... new Wimbledon Athletics Facebook page to educate the public, parents and ... abnormalities. About 2,000 people under the age of 25 die from sudden cardiac ...
Breaking Medicine News(10 mins):